EUVIMEDEUVIMED entdecken
Open Access

Outcomes Following Early Postoperative Adjuvant Radiosurgery for Brain Metastases

Evan D Bander, Tarek Y El Ahmadieh, Justin Chen, Anne S Reiner, Samantha Brown, Alexandra M Giantini-Larsen, Robert J Young, Kathryn Beal, Brandon S Imber, Luke R G Pike, Cameron W Brennan, Viviane Tabar und 2 weitere

JAMA Network Open · 31.10.2023 · 6 (10) · e2340654

DOI: 10.1001/jamanetworkopen.2023.40654 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 31.10.2023. Verfasst von Evan D Bander und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery and Brain Metastasis Center, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Radiosurgery, Drug-Related Side Effects and Adverse Reactions, Brain Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Adjuvant stereotactic radiosurgery (SRS) enhances the local control of resected brain metastases (BrM). However, the risks of local failure (LF) and potential for posttreatment adverse radiation effects (PTRE) after early postoperative adjuvant SRS have not yet been established.

Objective

To evaluate whether adjuvant SRS delivered within a median of 14 days after surgery is associated with improved LF without a concomitant increase in PTRE. Design, Setting, and Participants This prospective cohort study examines a clinical workflow (RapidRT) that was implemented from 2019 to 2022 to deliver SRS to surgical patients within a median of 14 days, ensuring all patients were treated within 30 days postoperatively. This prospective cohort was compared with a historical cohort (StanRT) of patients with BrM resected between 2013 and 2019 to assess the association of the RapidRT workflow with LF and PTRE. The 2 cohorts were combined to identify optimal SRS timing, with a median follow-up of 3.3 years for survivors. Exposure Timing of adjuvant SRS (14, 21, and 30 days postoperatively). Main Outcomes and Measures LF and PTRE, according to modified Response Assessment in Neuro-Oncology Brain Metastases criteria.

Results

There were 438 patients (265 [60.5%] female patients; 23 [5.3%] Asian, 27 [6.2%] Black, and 364 [83.1%] White patients) with a mean (SD) age of 62 (13) years; 377 were in the StanRT cohort and 61 in the RapidRT cohort. LF and PTRE rates at 1 year were not significantly different between RapidRT and StanRT cohorts. Timing of SRS was associated with radiographic PTRE. Patients receiving radiation within 14 days had the highest 1-year PTRE rate (18.08%; 95% CI, 8.31%-30.86%), and patients receiving radiation between 22 and 30 days had the lowest 1-year PTRE rate (4.10%; 95% CI, 1.52%-8.73%; P = .03). LF rates were highest for patients receiving radiation more than 30 days from surgery (10.65%; 95% CI, 6.90%-15.32%) but comparable for patients receiving radiation within 14 days, between 15 and 21 days, and between 22 and 30 days (≤14 days: 5.12%; 95% CI, 0.86%-15.60%; 15 to ≤21 days: 3.21%; 95% CI, 0.59%-9.99%; 22 to ≤30 days: 6.58%; 95% CI, 3.06%-11.94%; P = .20). Conclusions and Relevance In this cohort study of adjuvant SRS timing following surgical resection of BrM, the optimal timing for adjuvant SRS appears to be within 22 to 30 days following surgery. The findings of this study suggest that this timing allows for a balanced approach that minimizes the risks associated with LF and PTRE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryDrug-Related Side Effects and Adverse ReactionsBrain NeoplasmsHumansFemaleMiddle AgedMaleProspective StudiesCohort StudiesAdjuvants, Immunologic

Substanzen

Adjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Neurosurgery and Brain Metastasis Center, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Neurosurgery, New York Presbyterian Hospital/Weill Cornell Medical College, New York.
  • Department of Neurosurgery, Loma Linda University Health, Loma Linda, California.
  • Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiation Oncology and Brain Metastasis Center, Memorial Sloan Kettering Cancer Center, New York, New York.

Förderung

  • NCI NIH HHS

Zitieren

APA

Bander, E. D., El Ahmadieh, T. Y., Chen, J., Reiner, A. S., Brown, S., Giantini-Larsen, A. M., Young, R. J., Beal, K., Imber, B. S., Pike, L. R. G., Brennan, C. W., Tabar, V., Panageas, K. S., & Moss, N. S. (2023). Outcomes Following Early Postoperative Adjuvant Radiosurgery for Brain Metastases. JAMA Network Open, 6(10), e2340654. https://doi.org/10.1001/jamanetworkopen.2023.40654

Vancouver

Bander ED, El Ahmadieh TY, Chen J, Reiner AS, Brown S, Giantini-Larsen AM, et al. Outcomes Following Early Postoperative Adjuvant Radiosurgery for Brain Metastases. JAMA Network Open. 2023;6(10):e2340654. doi:10.1001/jamanetworkopen.2023.40654

BibTeX
@article{Bander2023,
  author = {Bander, Evan D and El Ahmadieh, Tarek Y and Chen, Justin and Reiner, Anne S and Brown, Samantha and Giantini-Larsen, Alexandra M and Young, Robert J and Beal, Kathryn and Imber, Brandon S and Pike, Luke R G and Brennan, Cameron W and Tabar, Viviane and Panageas, Katherine S and Moss, Nelson S},
  title = {Outcomes Following Early Postoperative Adjuvant Radiosurgery for Brain Metastases},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {10},
  pages = {e2340654},
  doi = {10.1001/jamanetworkopen.2023.40654}
}
Kostenlos starten →